# LENZ (Lenz Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Lenz Therapeutics, Inc. reported $12.36M in revenue and a net loss of $140.3M for the trailing twelve months ended September 30, 2026 (down 72.9% year over year), with a 82.0% gross margin and a -1211.2% operating margin.

- Canonical: https://convexityos.com/fundamentals/LENZ
- Markdown: https://convexityos.com/fundamentals/LENZ.md
- SEC CIK: 0001815776
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:47 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001815776&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $12.36M | -72.9% YoY |
| Operating Income | TTM | -$149.7M | -1211.2% margin |
| Net Income | TTM | -$140.3M | -1135.0% net margin |
| Diluted EPS | TTM | -$4.46 | Split-adjusted |
| Free Cash Flow | TTM | -$127.7M | -1033.3% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $30.55M | Total debt: $460K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $19.09M | $0 | -- | -- | -- | -- |
| Cost of Revenue | $418K | $0 | -- | -- | -- | -- |
| **Gross Profit** | $18.67M | $0 | -- | -- | -- | -- |
| Research & Development | $18.67M | $29.80M | $59.50M | $72.79M | $37.93M | $9.12M |
| Selling, General & Admin | $91.14M | $28.81M | $12.93M | -- | -- | -- |
| Total Operating Expenses | -- | $58.61M | $72.43M | $105.6M | $60.44M | $13.50M |
| **Operating Income** | -$91.14M | -$58.61M | -$72.43M | -$105.6M | -$60.44M | -$13.50M |
| **EBITDA** | -$90.85M | -$58.55M | -$72.41M | -$103.3M | -$59.71M | -$13.38M |
| Interest Income | $9.76M | $8.55M | $2.19M | -- | -- | -- |
| Income Before Tax | -$81.62M | -$49.77M | -$70.15M | -- | -- | -- |
| Income Tax Expense | $502K | $1.0K | -$179K | $0 | $0 | $0 |
| **Net Income** | -$82.13M | -$49.77M | -$69.97M | -$101.1M | -$70.76M | -$68.37M |
| Basic EPS | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
| **Diluted EPS** | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
| Basic Shares Outstanding | 28.8M | 21.3M | 2.0M | 54.9M | 28.9M | 2.3M |
| Diluted Shares Outstanding | 28.8M | 21.3M | 2.0M | 54.9M | 28.9M | 2.3M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $3.38M | $5.49M | $1.90M | $1.59M | $12.50M | $5.00M | $0 | -- |
| Cost of Revenue | $454K | $280K | $1.08M | $418K | $0 | $0 | $0 | -- |
| **Gross Profit** | $2.93M | $5.21M | $825K | $1.17M | $12.50M | $5.00M | $0 | -- |
| Research & Development | $0 | $0 | $0 | $0 | $3.79M | $9.06M | $5.82M | $5.87M |
| Selling, General & Admin | $35.85M | $39.38M | $44.96M | $39.63M | $27.60M | $12.80M | $11.11M | $9.36M |
| Total Operating Expenses | -- | -- | -- | -- | $31.39M | $21.86M | $16.93M | $15.22M |
| **Operating Income** | -$32.92M | -$34.17M | -$44.13M | -$38.46M | -$18.89M | -$16.86M | -$16.93M | -$15.22M |
| **EBITDA** | -$32.81M | -$34.06M | -$44.02M | -$38.36M | -$18.76M | -$16.84M | -$16.89M | -$15.20M |
| Interest Income | $1.99M | $2.27M | $2.64M | $2.99M | $2.20M | $2.25M | $2.32M | $2.57M |
| Income Before Tax | -$30.97M | -$31.91M | -- | -- | -$16.70M | -$14.41M | -- | -- |
| Income Tax Expense | $0 | $3.0K | -- | -- | $0 | $500K | -- | -- |
| **Net Income** | -$30.97M | -$31.92M | -$41.49M | -$35.90M | -$16.70M | -$14.91M | -$14.62M | -$12.65M |
| Basic EPS | -$0.99 | -$1.02 | -$1.32 | -- | -$0.59 | -$0.53 | -$0.53 | -- |
| **Diluted EPS** | -$0.99 | -$1.02 | -$1.32 | -- | -$0.59 | -$0.53 | -$0.53 | -- |
| Basic Shares Outstanding | 31.4M | 31.4M | 31.4M | -- | 28.5M | 28.1M | 27.5M | -- |
| Diluted Shares Outstanding | 31.4M | 31.4M | 31.4M | -- | 28.5M | 28.1M | 27.5M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $25.18M | $20.16M | $35.14M | $47.73M | $377.0M | $19.78M |
| Short-Term Investments | -- | -- | $30.65M | $220.5M | $0 | -- |
| **Cash & Short-Term Investments** | $292.3M | $209.1M | $184.3M | $283.6M | $377.0M | $19.78M |
| Accounts Receivable, Net | $329K | $0 | -- | -- | -- | -- |
| Inventory | $2.94M | $0 | -- | -- | -- | -- |
| **Total Current Assets** | $301.4M | $211.9M | $67.24M | $275.4M | $381.7M | $21.10M |
| Property, Plant & Equipment, Net | $1.19M | $651K | $54K | $22.63M | $6.51M | $1.46M |
| Long-Term Investments | -- | -- | $0 | $15.32M | $0 | -- |
| Other Non-Current Assets | $2.54M | $1.40M | $21K | $1.29M | $454K | -- |
| **Total Non-Current Assets** | $4.46M | $3.39M | $3.13M | $46.54M | $20.25M | $1.46M |
| **Total Assets** | $305.9M | $215.3M | $70.38M | $321.9M | $402.0M | $22.56M |
| Accounts Payable | $4.17M | $4.26M | $5.71M | $2.61M | $2.45M | $630K |
| Deferred Revenue (Current) | $0 | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $21.19M | $10.41M | $18.51M | $13.04M | $12.14M | $32.05M |
| Other Non-Current Liabilities | -- | $0 | $121K | $10.82M | $0 | $316K |
| **Total Non-Current Liabilities** | $350K | $814K | $1.18M | $12.57M | $5.79M | $316K |
| **Total Liabilities** | $21.54M | $11.22M | $19.70M | $25.61M | $17.94M | $32.36M |
| **Total Debt (incl. Leases)** | $815K | $1.31M | $362K | $5.79M | $11.28M | -- |
| Common Stock | $1.0K | $1.0K | $10K | $1.0K | $1.0K | -- |
| Retained Earnings | -$227.1M | -$145.0M | -$95.25M | -$242.4M | -$141.4M | -$70.59M |
| Accumulated Other Comp. Income | $242K | $196K | $6.0K | -$1.05M | $0 | -- |
| **Total Stockholders' Equity** | $284.3M | $204.1M | -$92.71M | -$24.17M | $384.1M | -$65.41M |
| Total Equity | $284.3M | $204.1M | -$92.71M | -$24.17M | $384.1M | -$65.41M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $30.55M | $24.21M | $24.77M | $25.18M | $25.40M | $37.61M | $23.04M | $20.16M |
| **Cash & Short-Term Investments** | $197.3M | $220.0M | $258.4M | $292.3M | $202.2M | $209.6M | $194.1M | $209.1M |
| Accounts Receivable, Net | $913K | $442K | $343K | $329K | -- | -- | -- | $0 |
| Inventory | $4.76M | $4.12M | $3.50M | $2.94M | $949K | -- | -- | $0 |
| **Total Current Assets** | $206.9M | $233.3M | $268.4M | $301.4M | $207.0M | $213.6M | $197.9M | $211.9M |
| Property, Plant & Equipment, Net | $640K | $1.00M | $1.10M | $1.19M | $1.26M | $1.17M | $926K | $651K |
| Other Non-Current Assets | $1.79M | $1.79M | $2.45M | $2.54M | $1.60M | $1.60M | $1.40M | $1.40M |
| **Total Non-Current Assets** | $2.85M | $3.31M | $4.17M | $4.46M | $3.71M | $3.73M | $3.39M | $3.39M |
| **Total Assets** | $209.7M | $236.6M | $272.5M | $305.9M | $210.7M | $217.3M | $201.3M | $215.3M |
| Accounts Payable | $5.52M | $6.65M | $10.93M | $4.17M | $4.32M | $2.85M | $3.66M | $4.26M |
| Deferred Revenue (Current) | -- | $785K | -- | $0 | -- | -- | -- | -- |
| **Total Current Liabilities** | $17.75M | $17.21M | $25.81M | $21.19M | $16.32M | $10.40M | $8.57M | $10.41M |
| Other Non-Current Liabilities | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Total Non-Current Liabilities** | $0 | $122K | $237K | $350K | $461K | $569K | $673K | $814K |
| **Total Liabilities** | $17.75M | $17.33M | $26.04M | $21.54M | $16.78M | $10.97M | $9.24M | $11.22M |
| **Total Debt (incl. Leases)** | $460K | $569K | $673K | $815K | $954K | $1.05M | $1.18M | $1.31M |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$331.5M | -$300.5M | -$268.6M | -$227.1M | -$191.2M | -$174.5M | -$159.6M | -$145.0M |
| Accumulated Other Comp. Income | -$1.06M | -$629K | -$450K | $242K | $227K | $38K | $123K | $196K |
| **Total Stockholders' Equity** | $192.0M | $219.3M | $246.5M | $284.3M | $193.9M | $206.4M | $192.0M | $204.1M |
| Total Equity | $192.0M | $219.3M | $246.5M | $284.3M | $193.9M | $206.4M | $192.0M | $204.1M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$82.13M | -$49.77M | -$124.7M | -$101.1M | -$70.76M | -$68.37M |
| Depreciation & Amortization | $287K | $58K | $15K | $2.35M | $734K | $121K |
| Stock-Based Compensation | $12.55M | $6.37M | $1.34M | $13.53M | $7.87M | $177K |
| Change in Receivables | -$329K | $0 | -- | -- | -- | -- |
| Change in Inventory | -$4.28M | $0 | -- | -- | -- | -- |
| Change in Payables | -$90K | -$4.28M | $856K | $194K | $1.82M | $594K |
| **Operating Cash Flow** | -$69.17M | -$59.39M | -$60.38M | -$87.98M | -$52.85M | -$8.72M |
| Capital Expenditure | -$827K | -$468K | -$30K | -$6.59M | -$5.74M | -$1.54M |
| **Free Cash Flow** | -$70.00M | -$59.86M | -$60.41M | -$94.57M | -$58.59M | -$10.27M |
| Purchases of Investments | -$280.8M | -$241.9M | -$52.09M | -$405.5M | $0 | -- |
| **Investing Cash Flow** | -$75.67M | -$154.5M | -$29.62M | -$241.9M | -$5.74M | -$1.54M |
| Common Stock Issued | -- | $79.51M | $0 | -- | -- | -- |
| **Financing Cash Flow** | $149.7M | $199.0M | $80.70M | $597K | $417.5M | $30.08M |
| **Net Change in Cash** | $4.91M | -$14.87M | -$9.30M | -$329.2M | $358.9M | $19.81M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$30.97M | -$31.92M | -$41.49M | -$35.90M | -$16.70M | -$14.91M | -$14.62M | -$12.65M |
| Depreciation & Amortization | $109K | $110K | $111K | $107K | $125K | $19K | $36K | $25K |
| Stock-Based Compensation | $4.13M | $4.47M | $4.32M | $3.68M | $3.47M | $2.85M | $2.56M | $1.63M |
| Change in Receivables | -$471K | -$99K | -$14K | -$329K | $0 | $0 | $0 | -- |
| Change in Inventory | -$781K | $19K | -$889K | -$3.33M | -$949K | $0 | $0 | -- |
| Change in Payables | -$1.13M | -$4.28M | $6.76M | -$156K | $1.69M | -$857K | -$771K | $1.32M |
| **Operating Cash Flow** | -$22.31M | -$38.71M | -$33.58M | -$33.02M | -$8.59M | -$11.51M | -$16.05M | -$9.08M |
| Capital Expenditure | $0 | -$16K | -$18K | -$38K | -$439K | -$240K | -$110K | -$149K |
| **Free Cash Flow** | -$22.31M | -$38.73M | -$33.60M | -$33.06M | -$9.03M | -$11.75M | -$16.16M | -$9.23M |
| Purchases of Investments | -$9.10M | -$7.37M | -$16.06M | -$133.1M | -$56.31M | -$58.29M | -$33.09M | -$46.61M |
| **Investing Cash Flow** | $28.66M | $37.75M | $33.16M | -$89.81M | -$4.33M | -$414K | $18.89M | -$11.86M |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | $0 | -$85K |
| **Financing Cash Flow** | $0 | $395K | $14K | $122.6M | $598K | $26.49M | $44K | $53K |
| **Net Change in Cash** | $6.34M | -$564K | -$407K | -$220K | -$12.32M | $14.57M | $2.88M | -$20.89M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 97.8% | -- | -- | -- | -- | -- |
| **Operating Margin** | -477.5% | -- | -- | -- | -- | -- |
| **Net Profit Margin** | -430.3% | -- | -- | -- | -- | -- |
| Return on Equity (ROE) | -28.9% | -24.4% | -- | -- | -18.4% | -- |
| Return on Assets (ROA) | -26.8% | -23.1% | -99.4% | -31.4% | -17.6% | -303.0% |
| Current Ratio | 14.23x | 20.36x | 3.63x | 21.11x | 31.44x | 0.66x |
| Quick Ratio | 14.09x | 20.36x | 9.95x | 21.74x | 31.04x | 0.62x |
| Debt to Equity | 0.00x | 0.01x | -- | -- | 0.03x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 82.0% | 91.7% | 92.9% | 97.8% | -- | -- | -- | -- |
| **Operating Margin** | -1211.2% | -631.7% | -563.8% | -477.5% | -- | -- | -- | -- |
| **Net Profit Margin** | -1135.0% | -586.7% | -519.3% | -430.3% | -- | -- | -- | -- |
| Return on Equity (ROE) | -73.1% | -57.5% | -44.2% | -28.9% | -30.4% | -25.4% | -24.9% | -24.4% |
| Return on Assets (ROA) | -66.9% | -53.3% | -40.0% | -26.8% | -27.9% | -24.1% | -23.7% | -23.1% |
| Current Ratio | 11.66x | 13.55x | 10.40x | 14.23x | 12.69x | 20.54x | 23.09x | 20.36x |
| Quick Ratio | 11.39x | 13.31x | 10.26x | 14.09x | 12.63x | 20.16x | 22.65x | 20.36x |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x |
| **Revenue Growth (YoY)** | -72.9% | +9.7% | -- | -- | -- | -- | -- | -- |
| Gross Profit Growth (YoY) | -76.6% | +4.1% | -- | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
